<DOC>
	<DOCNO>NCT00344409</DOCNO>
	<brief_summary>To compare effectiveness KRN321 placebo treatment anemia cancer patient receive multi cycle platinum-containing chemotherapy</brief_summary>
	<brief_title>A Double-blind Study KRN321 Treatment Anemia Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>patient diagnose lung gynecological cancer patient receive platinum contain chemotherapy write informed consent hemoglobin concentration le 11 d/dL enrollment life expectancy 4 month hemolysis , gastrointestinal bleeding , postoperative bleeding iron deficiency megaloblastic anemia primary hematological disorder could cause anemia receive &gt; 2 RBC transfusion 4 week RBC transfusion within 2 week randomization prior treatment KRN321 receive erythropoetin therapy within 8 week treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>darbepoetin alfa</keyword>
	<keyword>anemia</keyword>
	<keyword>cancer patient</keyword>
	<keyword>platinum contain chemotherapy</keyword>
</DOC>